TC

24/09/2020 18:01

{I-bank focus}UBS starts Alibaba Health (00241) at HK$26

    UBS Global Research initiated coverage on Alibaba Health Information Technology (00241) with a "buy" rating and a target price of HK$26.
  The research house likes Ali Health for its potential to reshape the traditional pharmaceutical distribution model. It added that Ali Health could leverage off large e-commerce customers and merchants on the Taobao and Tmall platforms, and also other user flow on DingTalk and other OTO platforms such as Koubei. 
  UBS said current stock price mainly reflects the effect of COVID-19, but not fully the sector's long-growth potential; UBS forecast a 40% revenue CAGR over 2019-25 for sector leaders.

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

觀落陰:什麼是觀落陰?人人都可參加地府自由行?遊地獄到底係點?

帶你探索全新主頁!輕鬆探索精選資訊!

全新etnet健康網購 賞維他命D3 (價值$108) 齊齊提升免疫力